As the traditional repositories for data on pharmacology, medicinal chemistry, chemical biology and drug R&D results, journal outputs clearly have a central role in ADEV. However, the PubChem BioAssay (AID) ratio of "Literature Extracted" to the rest (mostly screening centres) is 1043727: 23844. While this is only 2% in relative assay numbers many of these 2% are in fact substantial screens encompassing millions of unpublished activity results linked to ~ 0.5 million CIDs in PubChem (but with the caveat that much of this is primary HTS data). It is also important to note that the erstwhile monopoly of journal papers as "primary data carriers" is further eroded by three other trends, a) the rapid proliferation of preprints (see 'Has the Time Come for Preprints in Chemistry?', 2017, 10.1021/acsomega.7b01190 and 'Meta-Research: Tracking the popularity and outcomes of all bioRxiv preprints', 2019, PMID 31017570) b) the emergence of open (web instantiated) electronic laboratory notebooks (ELNs) (see 'Open notebook science can maximize impact for rare disease projects', 2019, PMID 30689629 and 'Experiences with a researcher-centric ELN', 2015, PMID 29308130) and c) the coverage of at least the majority of exemplified structures extracted from full-text patents being openly available in PubChem that may both exceed and precede their publication in papers by several years ('Expanding opportunities for mining bioactive chemistry from patents', 2015, PMID 26194581).